Is it possible to benefit from the K-CAB 4th indication?

in competition with Fexuclu

Attention is focusing on whether HK inno.

 

N's new drug K-CAB for gastroesophageal reflux disease will succeed in providing additional indications.

 

Currently, K-CAB is being reimbursed to treat erosive and non-erosive gastroesophageal reflux disease and gastric ulcer.

 

In March 2019, K-CAB, which was first applied to the treatment of erosive and non-erosive gastroesophageal reflux disease, expanded its salary to the treatment of gastric ulcers in October last year.

 

According to industries on the 17th, the HIRA has started reviewing the benefit standards for K-CAB.

 

K-CAB has acquired a total of five indications so far.

 

Among them, health insurance benefits are applied to three treatments: erosive and non-erosive gastroesophageal reflux disease treatment and gastric ulcer treatment.

 

In the rest of the patients with peptic ulcers and chronic atrophic gastritis, antibiotic combination therapy for Helicobacter pylori eradication and maintenance indications after treatment with erosive gastroesophageal reflux disease remain non-payment.

 

HK inno.N is trying to being reimbursed for additional indications.

 

If K-CAB succeeds in making additional indications, Daewoong Pharmaceutical, which launched its benefit in July It is expected to gain an edge in competition with Fexuclu.

 

Fexuclu is currently only recognized for the treatment of erosive gastroesophageal reflux disease.

 

Fexuclu 10mg is expected to seek additional benefit as it has an indication of improving gastric mucosal lesions of acute gastritis and chronic gastritis.

 

Fexuclu is a P-CAB-based drug such as K-CAB, and has continued to be so popular that it recorded 2.6 billion won in outpatient prescription performance (based on UBIST) for two months as soon as it was released in July.

 

K-CAB, which has secured exclusive status as the only P-CAB drug since its launch in 2019, has seen a formidable competitive drug.

 

However, it is analyzed that K-CAB is still superior to Fexuclu due to its wide range of use, with medical care benefits applied to the current three indications.

 

On top of that, some predict that the gap will widen if additional indications are secured.

 

K-CAB recorded 60.6 billion won in outpatient prescriptions in the first half of this year, and is likely to surpass 100 billion won annually this year following last year.

 

HK inno.N also plans to lead the market by developing clinical trials to add preventive therapy indications for gastric and duodenal ulcers that induce nonsteroidal anti-inflammatory analgesics.